You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMetolazone
Accession NumberDB00524  (APRD01109)
TypeSmall Molecule
GroupsApproved
DescriptionA quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. [PubChem]
Structure
Thumb
Synonyms
2-Methyl-3-O-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone
7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide
7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-O-tolyl-6-quinazolinesulfonamide
Metolazon
Metolazona
Métolazone
Metolazonum
Zaroxolyn
External Identifiers
  • SR 720-22
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MetolazoneTablet2.5 mg/1OralAvera Mc Kennan Hospital2015-04-16Not applicableUs
MetolazoneTablet2.5 mg/1OralUpstate Pharma, LLC1973-11-27Not applicableUs
MetolazoneTablet2.5 mg/1OralAphena Pharma Solutions Tennessee, Llc1973-11-27Not applicableUs
MetolazoneTablet5 mg/1OralUpstate Pharma, LLC1973-11-27Not applicableUs
MetolazoneTablet10 mg/1OralUpstate Pharma, LLC1973-11-27Not applicableUs
ZaroxolynTablet5 mg/1OralUNITHER Manufacturing LLC1973-11-272016-01-13Us
ZaroxolynTablet2.5 mgOralSanofi Aventis Canada Inc1974-12-31Not applicableCanada
ZaroxolynTablet2.5 mg/1OralCarilion Materials Management1973-11-27Not applicableUs
ZaroxolynTablet5 mgOralAventis Pharma Inc1974-12-312003-07-22Canada
Zaroxolyn Tab 10mgTablet10 mgOralRhone Poulenc Rorer Canada Inc.1974-12-311998-08-12Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MetolazoneTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-12-19Not applicableUs
MetolazoneTablet5 mg/1OralEon Labs, Inc.2003-12-19Not applicableUs
MetolazoneTablet2.5 mg/1OralCardinal Health2011-01-14Not applicableUs
MetolazoneTablet5 mg/1OralMylan Institutional Inc.2005-02-01Not applicableUs
MetolazoneTablet5 mg/1OralMylan Pharmaceuticals Inc.2004-10-19Not applicableUs
MetolazoneTablet2.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-18Not applicableUs
MetolazoneTablet2.5 mg/1OralEon Labs, Inc.2003-12-19Not applicableUs
MetolazoneTablet5 mg/1OralCardinal Health2011-01-14Not applicableUs
MetolazoneTablet5 mg/1OralPhysicians Total Care, Inc.2004-04-27Not applicableUs
MetolazoneTablet10 mg/1OralMylan Pharmaceuticals Inc.2004-10-19Not applicableUs
MetolazoneTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-18Not applicableUs
MetolazoneTablet10 mg/1OralEon Labs, Inc.2003-12-19Not applicableUs
MetolazoneTablet5 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2006-11-15Not applicableUs
MetolazoneTablet2.5 mg/1OralPhysicians Total Care, Inc.2004-07-06Not applicableUs
MetolazoneTablet2.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-12-19Not applicableUs
MetolazoneTablet2.5 mg/1OralMylan Institutional Inc.2005-04-15Not applicableUs
MetolazoneTablet2.5 mg/1OralMylan Pharmaceuticals Inc.2004-01-06Not applicableUs
MetolazoneTablet10 mg/1OralCarilion Materials Management2004-10-19Not applicableUs
MetolazoneTablet10 mg/1OralPhysicians Total Care, Inc.2004-07-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DiuloNot Available
DiuremCipla
MetadureMicro Labs
MetenixIFET
MetolazNavana
MetoralDr. Reddy's
MetozCentaur
MetozoneYing Yuan
MykroxCelltech
PavedalPharma Investi
ZytanixZydus
Brand mixturesNot Available
SaltsNot Available
Categories
UNIITZ7V40X7VX
CAS number17560-51-9
WeightAverage: 365.835
Monoisotopic: 365.06008979
Chemical FormulaC16H16ClN3O3S
InChI KeyAQCHWTWZEMGIFD-UHFFFAOYSA-N
InChI
InChI=1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23)
IUPAC Name
7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide
SMILES
CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=CC=CC=C1C)S(N)(=O)=O
Pharmacology
IndicationFor the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class.
Structured Indications
PharmacodynamicsMetolazone is a quinazoline diuretic, with properties generally similar to the thiazide diuretics. A proximal action of metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration. This action has been demonstrated in animals by micropuncture studies.
Mechanism of actionThe actions of metolazone result from interference with the renal tubular mechanism of electrolyte reabsorption. Metolazone acts primarily to inhibit sodium reabsorption at the cortical diluting site and to a lesser extent in the proximal convoluted tubule. Sodium and chloride ions are excreted in approximately equivalent amounts. The increased delivery of sodium to the distal tubular exchange site results in increased potassium excretion. Metolazone does not inhibit carbonic anhydrase. The antihypertensive mechanism of action of metolazone is not fully understood but is presumed to be related to its saluretic and diuretic properties.
TargetKindPharmacological actionActionsOrganismUniProt ID
Solute carrier family 12 member 3Proteinyes
inhibitor
HumanP55017 details
Related Articles
AbsorptionPeak blood levels are obtained within 2 to 4 hours of oral administration. The rate and extent of absorption are formulation dependent.
Volume of distributionNot Available
Protein binding50-70% bound to erythrocytes, up to 33% bound to plasma proteins, 2-5% of the drug in circulation is unbound
Metabolism

Not substantially metabolized. 70-95% is excreted unchanged in urine via glomerular filtration and active tubular secretion. Undergoes enterohepatic recycling.

Route of eliminationMost of the drug is excreted in the unconverted form in the urine.
Half lifeApproximately 14 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include difficulty breathing, dizziness, dizziness on standing up, drowsiness, fainting, irritation of the stomach and intestines, and lethargy leading to coma.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Metolazone Action PathwayDrug actionSMP00105
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Metolazone.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Metolazone.Experimental, Illicit
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Metolazone.Experimental, Illicit
5-androstenedione5-androstenedione may increase the hypokalemic activities of Metolazone.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Metolazone.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Metolazone.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Metolazone is combined with Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Aceclofenac.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Metolazone is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Metolazone.Withdrawn
AcetovanilloneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Acetovanillone.Investigational
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Metolazone is combined with Acetyldigitoxin.Approved
Acetylsalicylic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Metolazone can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Adapalene.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Metolazone.Experimental
AlclometasoneAlclometasone may increase the hypokalemic activities of Metolazone.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Metolazone.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Metolazone.Experimental
AlfacalcidolMetolazone may increase the hypercalcemic activities of Alfacalcidol.Approved, Nutraceutical
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Metolazone.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Metolazone.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Metolazone is combined with Aliskiren.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Metolazone.Approved
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Metolazone.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Metolazone.Experimental, Illicit
AlprenololMetolazone may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanMetolazone may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Metolazone.Approved
AmifostineMetolazone may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Metolazone is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Metolazone is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Metolazone.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Metolazone is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Metolazone is combined with Amyl Nitrite.Approved
AnecortaveAnecortave may increase the hypokalemic activities of Metolazone.Investigational
AnisodamineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Metolazone can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Antipyrine.Approved
AnvirzelThe risk or severity of adverse effects can be increased when Metolazone is combined with Anvirzel.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Metolazone is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Metolazone is combined with Apraclonidine.Approved
ApremilastThe therapeutic efficacy of Metolazone can be decreased when used in combination with Apremilast.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Metolazone.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Metolazone.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Metolazone.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Metolazone is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Metolazone is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Metolazone.Approved
Atracurium besylateThe serum concentration of Metolazone can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Metolazone can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Metolazone is combined with Azilsartan medoxomil.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Metolazone.Investigational
BalsalazideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Metolazone.Approved
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Metolazone.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Metolazone.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Metolazone is combined with Barnidipine.Approved
BeclomethasoneBeclomethasone may increase the hypokalemic activities of Metolazone.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Metolazone.Approved, Investigational
BenactyzineThe serum concentration of Metolazone can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Metolazone is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Metolazone.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Metolazone.Withdrawn
BenoxaprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Metolazone can be increased when it is combined with Benzatropine.Approved
BepridilMetolazone may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Metolazone.Approved
BethanidineBethanidine may increase the hypotensive activities of Metolazone.Approved
Betulinic AcidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Betulinic Acid.Investigational
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Metolazone.Experimental, Illicit, Withdrawn
BimatoprostMetolazone may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Metolazone can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Metolazone is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Metolazone is combined with Bortezomib.Approved, Investigational
BosentanMetolazone may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Metolazone is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Metolazone.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Metolazone.Approved
BromfenacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Metolazone is combined with Bromocriptine.Approved, Investigational
BucillamineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Metolazone.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Metolazone.Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Metolazone is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Metolazone is combined with Bupivacaine.Approved, Investigational
BupranololMetolazone may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Metolazone.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Metolazone.Approved, Illicit, Vet Approved
CalcidiolMetolazone may increase the hypercalcemic activities of Calcidiol.Approved, Nutraceutical
CalcipotriolMetolazone may increase the hypercalcemic activities of Calcipotriol.Approved
CalcitriolMetolazone may increase the hypercalcemic activities of Calcitriol.Approved, Nutraceutical
CalciumMetolazone may decrease the excretion rate of Calcium which could result in a higher serum level.Nutraceutical
Calcium AcetateMetolazone may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
Calcium carbonateMetolazone may decrease the excretion rate of Calcium carbonate which could result in a higher serum level.Approved
Calcium ChlorideMetolazone may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
Calcium citrateMetolazone may decrease the excretion rate of Calcium citrate which could result in a higher serum level.Approved
Calcium glubionateMetolazone may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateMetolazone may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateMetolazone may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Metolazone is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Metolazone is combined with Candesartan.Approved
CandoxatrilMetolazone may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Metolazone is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Metolazone is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Metolazone is combined with Carbetocin.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Metolazone.Illicit, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Metolazone.Withdrawn
CarprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Metolazone.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Metolazone is combined with Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Metolazone.Approved, Investigational
ChloroquineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Metolazone is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Metolazone can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Metolazone is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Metolazone.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Metolazone.Approved
CholecalciferolMetolazone may increase the hypercalcemic activities of Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Metolazone.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Metolazone.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Metolazone is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Metolazone is combined with Cilnidipine.Approved
CitalopramCitalopram may increase the hyponatremic activities of Metolazone.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Metolazone is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Metolazone.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Metolazone.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Metolazone.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Metolazone is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Metolazone is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Metolazone is combined with Clonidine.Approved
ClonixinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Clonixin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Metolazone is combined with Clozapine.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Metolazone.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Metolazone is combined with Conivaptan.Approved, Investigational
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Metolazone.Approved
CryptenamineMetolazone may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe therapeutic efficacy of Metolazone can be decreased when used in combination with Curcumin.Investigational
CyclopentolateThe serum concentration of Metolazone can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Metolazone is combined with Cyclophosphamide.Approved, Investigational
CyclothiazideMetolazone may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneThe therapeutic efficacy of Metolazone can be decreased when used in combination with D-Limonene.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Metolazone is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the hyponatremic activities of Metolazone.Investigational
DarifenacinThe serum concentration of Metolazone can be increased when it is combined with Darifenacin.Approved, Investigational
DebrisoquinMetolazone may increase the hypotensive activities of Debrisoquin.Approved
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Metolazone.Investigational
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Metolazone.Investigational
DeserpidineMetolazone may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Metolazone is combined with Desflurane.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Metolazone is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Metolazone can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Metolazone.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Metolazone.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Metolazone.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Metolazone.Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Metolazone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Metolazone.Vet Approved
DexetimideThe serum concentration of Metolazone can be increased when it is combined with Dexetimide.Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Metolazone.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Metolazone is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Metolazone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Metolazone.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Metolazone.Approved
DiazoxideThe risk or severity of adverse effects can be increased when Metolazone is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Metolazone is combined with Diclofenamide.Approved
DicyclomineThe serum concentration of Metolazone can be increased when it is combined with Dicyclomine.Approved
DiflorasoneDiflorasone may increase the hypokalemic activities of Metolazone.Approved
DiflunisalThe therapeutic efficacy of Metolazone can be decreased when used in combination with Diflunisal.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Metolazone.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Metolazone.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Metolazone is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Metolazone is combined with Digoxin.Approved
DihydralazineMetolazone may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Metolazone.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Metolazone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Metolazone.Experimental, Illicit
DihydrotachysterolMetolazone may increase the hypercalcemic activities of Dihydrotachysterol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Metolazone.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Metolazone is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Metolazone.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Metolazone.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Metolazone is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Metolazone.Approved
DofetilideMetolazone may increase the QTc-prolonging activities of Dofetilide.Approved
DorzolamideMetolazone may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Metolazone is combined with Doxazosin.Approved
DoxercalciferolMetolazone may increase the hypercalcemic activities of Doxercalciferol.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Metolazone.Investigational
DroxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Droxicam.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Metolazone.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Metolazone.Approved
DuloxetineMetolazone may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Duvelisib.Investigational
E6201The therapeutic efficacy of Metolazone can be decreased when used in combination with E6201.Investigational
EbselenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ebselen.Investigational
EfonidipineMetolazone may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Metolazone is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Metolazone is combined with Enalapril.Approved, Vet Approved
EnalaprilatMetolazone may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Metolazone.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Metolazone can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Eplerenone.Approved
EpoprostenolMetolazone may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Metolazone is combined with Eprosartan.Approved
EquileninEquilenin may increase the hypokalemic activities of Metolazone.Experimental
EquilinEquilin may increase the hypokalemic activities of Metolazone.Approved
ErgocalciferolMetolazone may increase the hypercalcemic activities of Ergocalciferol.Approved, Nutraceutical
EscitalopramEscitalopram may increase the hyponatremic activities of Metolazone.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Metolazone.Approved
EstroneEstrone may increase the hypokalemic activities of Metolazone.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Metolazone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Metolazone is combined with Etacrynic acid.Approved
EtanerceptThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Metolazone.Approved
EthopropazineThe serum concentration of Metolazone can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Metolazone.Approved, Illicit
EtodolacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etofenamate.Approved
EtoperidoneEtoperidone may increase the hyponatremic activities of Metolazone.Approved
EtoricoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Metolazone.Illicit, Vet Approved
Evening primrose oilThe therapeutic efficacy of Metolazone can be decreased when used in combination with Evening primrose oil.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Metolazone.Approved, Investigational
exisulindThe therapeutic efficacy of Metolazone can be decreased when used in combination with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Metolazone is combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Fenbufen.Approved
FenoldopamMetolazone may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Metolazone.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metolazone.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Metolazone can be increased when it is combined with Fesoterodine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Metolazone is combined with Fimasartan.Approved
FloctafenineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Floctafenine.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Metolazone.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Metolazone.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Metolazone.Approved, Investigational
FlunixinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Flunixin.Vet Approved
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Metolazone.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Metolazone.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Metolazone.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Metolazone.Approved
FluoxetineFluoxetine may increase the hyponatremic activities of Metolazone.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Metolazone.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Metolazone.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Metolazone.Approved
FlurbiprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Flurbiprofen.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Metolazone.Approved
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Metolazone.Approved
FluvoxamineFluvoxamine may increase the hyponatremic activities of Metolazone.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Metolazone.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Metolazone.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Metolazone.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Metolazone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Metolazone is combined with Furosemide.Approved, Vet Approved
Gallamine TriethiodideThe serum concentration of Metolazone can be increased when it is combined with Gallamine Triethiodide.Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Metolazone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Metolazone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Metolazone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Metolazone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Metolazone.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Metolazone.Approved
GlycopyrroniumThe serum concentration of Metolazone can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuanabenzMetolazone may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Metolazone.Approved
GuanethidineMetolazone may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Metolazone is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Metolazone.Investigational
HalothaneThe risk or severity of adverse effects can be increased when Metolazone is combined with Halothane.Approved, Vet Approved
HE3286HE3286 may increase the hypokalemic activities of Metolazone.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Metolazone.Approved, Illicit
HexamethoniumThe serum concentration of Metolazone can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved
HigenamineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Higenamine.Investigational
HMPL-004The therapeutic efficacy of Metolazone can be decreased when used in combination with HMPL-004.Investigational
HomatropineThe serum concentration of Metolazone can be increased when it is combined with Homatropine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Metolazone.Approved
HydralazineThe risk or severity of adverse effects can be increased when Metolazone is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Metolazone is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Metolazone.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
HydroflumethiazideMetolazone may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Metolazone.Approved, Illicit
HyoscyamineThe serum concentration of Metolazone can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Metolazone can be decreased when used in combination with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Metolazone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Metolazone is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Metolazone is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Metolazone.Approved
IndalpineIndalpine may increase the hyponatremic activities of Metolazone.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Metolazone is combined with Indapamide.Approved
IndenololMetolazone may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminMetolazone may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Metolazone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Metolazone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Metolazone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Metolazone.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Metolazone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Metolazone.Approved
Ipratropium bromideThe serum concentration of Metolazone can be increased when it is combined with Ipratropium bromide.Approved
IproclozideIproclozide may increase the hypotensive activities of Metolazone.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Metolazone.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Metolazone is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Metolazone.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Metolazone.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Metolazone is combined with Isoflurane.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Metolazone.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Metolazone is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Metolazone is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Metolazone is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Metolazone.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Metolazone.Investigational
IvabradineMetolazone may increase the arrhythmogenic activities of Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Kebuzone.Experimental
KetanserinMetolazone may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Metolazone.Approved
KetoprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Metolazone is combined with Labetalol.Approved
LacidipineMetolazone may increase the hypotensive activities of Lacidipine.Approved
LatanoprostMetolazone may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineMetolazone may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Metolazone is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Metolazone is combined with Levobupivacaine.Approved
LevodopaMetolazone may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Metolazone.Approved
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Metolazone.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Metolazone.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Metolazone is combined with Levosimendan.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Metolazone.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Metolazone.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Metolazone.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Metolazone is combined with Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Lisofylline.Investigational
LithiumMetolazone may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Metolazone.Illicit
LofexidineMetolazone may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Metolazone is combined with Losartan.Approved
LoxoprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanMetolazone may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Metolazone can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineMetolazone may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Metolazone is combined with Mannitol.Approved, Investigational
MasoprocolThe therapeutic efficacy of Metolazone can be decreased when used in combination with Masoprocol.Approved
ME-609ME-609 may increase the hypokalemic activities of Metolazone.Investigational
MebanazineMebanazine may increase the hypotensive activities of Metolazone.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Metolazone is combined with Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Metolazone.Approved
Mefenamic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Metolazone.Vet Approved
MeloxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Metolazone can be decreased when used in combination with Metamizole.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Metolazone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Metolazone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Metolazone.Approved, Illicit
MethanthelineThe serum concentration of Metolazone can be increased when it is combined with Methantheline.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Metolazone is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Metolazone.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metolazone.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Metolazone is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Metolazone.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Metolazone.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Metolazone is combined with Metipranolol.Approved
MetixeneThe serum concentration of Metolazone can be increased when it is combined with Metixene.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Metolazone.Approved, Investigational
MetyrosineMetolazone may increase the hypotensive activities of Metyrosine.Approved
MibefradilMetolazone may increase the hypotensive activities of Mibefradil.Withdrawn
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Metolazone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Metolazone.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Metolazone.Approved
MinaprineMinaprine may increase the hypotensive activities of Metolazone.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Metolazone.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Metolazone.Approved, Investigational
MizoribineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Metolazone.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Metolazone is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Metolazone.Approved
MometasoneMometasone may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Metolazone.Approved, Investigational
MoxonidineMetolazone may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolic acid.Approved
N-butylscopolammonium bromideThe serum concentration of Metolazone can be increased when it is combined with N-butylscopolammonium bromide.Vet Approved
NabiloneThe risk or severity of adverse effects can be increased when Metolazone is combined with Nabilone.Approved, Investigational
NabumetoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Metolazone is combined with Nadolol.Approved
NafamostatThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nafamostat.Investigational
NaftifineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Naftifine.Approved
NaftopidilMetolazone may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Metolazone.Approved
NaproxenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Metolazone.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Metolazone.Investigational
NCX 4016The therapeutic efficacy of Metolazone can be decreased when used in combination with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Metolazone is combined with Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the hyponatremic activities of Metolazone.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Metolazone is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Metolazone.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Metolazone is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Metolazone.Approved
NifedipineThe risk or severity of adverse effects can be increased when Metolazone is combined with Nifedipine.Approved
Niflumic AcidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineMetolazone may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineMetolazone may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Metolazone.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Metolazone.Approved
NitrendipineMetolazone may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Metolazone is combined with Nitric Oxide.Approved
NitroaspirinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Metolazone is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Metolazone.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Metolazone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Metolazone.Approved, Illicit
NVA237The serum concentration of Metolazone can be increased when it is combined with NVA237.Investigational
ObinutuzumabMetolazone may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Metolazone.Withdrawn
Oleoyl estroneOleoyl estrone may increase the hypokalemic activities of Metolazone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Metolazone.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Metolazone.Approved
OlopatadineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Olsalazine.Approved
OmapatrilatMetolazone may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Metolazone.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Metolazone.Approved
OrgoteinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Metolazone can be increased when it is combined with Orphenadrine.Approved
OuabainThe risk or severity of adverse effects can be increased when Metolazone is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Metolazone is combined with Oxcarbazepine.Approved
OxprenololMetolazone may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe serum concentration of Metolazone can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metolazone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Metolazone.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Oxyphenbutazone.Withdrawn
OxyphenoniumThe serum concentration of Metolazone can be increased when it is combined with Oxyphenonium.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Metolazone is combined with Paclitaxel.Approved, Vet Approved
PancuroniumThe serum concentration of Metolazone can be increased when it is combined with Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Metolazone is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Metolazone.Approved
ParecoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Metolazone.Approved
ParicalcitolMetolazone may increase the hypercalcemic activities of Paricalcitol.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Metolazone.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Metolazone is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Metolazone.Approved, Vet Approved
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved, Vet Approved
PentoliniumThe serum concentration of Metolazone can be increased when it is combined with Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Metolazone.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Metolazone is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Metolazone.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Metolazone.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Metolazone.Approved, Withdrawn
PheniprazinePheniprazine may increase the hypotensive activities of Metolazone.Withdrawn
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved
PhenoxybenzamineMetolazone may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Metolazone.Withdrawn
PhentolamineMetolazone may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Metolazone.Approved, Vet Approved, Withdrawn
PimecrolimusThe therapeutic efficacy of Metolazone can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilMetolazone may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Metolazone is combined with Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Metolazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Pipamperone.Approved
PipecuroniumThe serum concentration of Metolazone can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Metolazone.Approved
PirenzepineThe serum concentration of Metolazone can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Pirfenidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Metolazone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Metolazone.Approved
PiroxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Metolazone.Withdrawn
PolythiazideMetolazone may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Metolazone is combined with Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Metolazone.Approved, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Metolazone.Approved, Nutraceutical
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Metolazone.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Metolazone.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Metolazone.Experimental
PrimidonePrimidone may increase the orthostatic hypotensive activities of Metolazone.Approved, Vet Approved
ProcaterolProcaterol may increase the hypokalemic activities of Metolazone.Approved
ProcyclidineThe serum concentration of Metolazone can be increased when it is combined with Procyclidine.Approved
PropacetamolThe therapeutic efficacy of Metolazone can be decreased when used in combination with Propacetamol.Approved
PropanthelineThe serum concentration of Metolazone can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Metolazone can be increased when it is combined with Propiverine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Metolazone is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Metolazone is combined with Propranolol.Approved, Investigational
PTC299The therapeutic efficacy of Metolazone can be decreased when used in combination with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Metolazone is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Metolazone is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Metolazone can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Metolazone.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Metolazone.Approved
RasagilineRasagiline may increase the hypotensive activities of Metolazone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Metolazone.Approved
RemikirenRemikiren may increase the hypotensive activities of Metolazone.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Metolazone.Approved, Investigational
RescinnamineMetolazone may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Metolazone.Approved
ResveratrolThe therapeutic efficacy of Metolazone can be decreased when used in combination with Resveratrol.Experimental, Investigational
RilmenidineMetolazone may increase the hypotensive activities of Rilmenidine.Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Metolazone.Approved
RiociguatThe risk or severity of adverse effects can be increased when Metolazone is combined with Riociguat.Approved
RisperidoneMetolazone may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Metolazone.Approved
RituximabMetolazone may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Metolazone is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Metolazone is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Metolazone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Metolazone is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Metolazone is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Metolazone.Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Metolazone.Approved
SalsalateThe therapeutic efficacy of Metolazone can be decreased when used in combination with Salsalate.Approved
SaprisartanMetolazone may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Metolazone.Approved
ScopolamineThe serum concentration of Metolazone can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe serum concentration of Metolazone can be increased when it is combined with Scopolamine butylbromide.Approved
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Metolazone.Approved, Investigational, Vet Approved
SelexipagMetolazone may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe therapeutic efficacy of Metolazone can be decreased when used in combination with Seratrodast.Approved, Investigational
SertralineSertraline may increase the hyponatremic activities of Metolazone.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Metolazone is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Metolazone.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Metolazone.Approved, Investigational
SitaxentanMetolazone may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Metolazone is combined with Sodium Nitrite.Approved
SolifenacinThe serum concentration of Metolazone can be increased when it is combined with Solifenacin.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Metolazone.Approved
SpiraprilMetolazone may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Metolazone.Approved
SRT501The therapeutic efficacy of Metolazone can be decreased when used in combination with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Metolazone is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Metolazone.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Sulindac.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Metolazone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Metolazone is combined with Sulpiride.Approved
SuprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Suprofen.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Metolazone.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Metolazone is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Metolazone.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Metolazone is combined with Telmisartan.Approved, Investigational
TemocaprilMetolazone may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Metolazone is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Metolazone.Approved
TeriflunomideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Teriflunomide.Approved
TerlipressinMetolazone may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Metolazone is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Metolazone.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Metolazone.Investigational
ThiopentalThiopental may increase the orthostatic hypotensive activities of Metolazone.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Metolazone is combined with Thioridazine.Approved
Tiaprofenic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneMetolazone may increase the hypotensive activities of Tibolone.Approved
TicrynafenMetolazone may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Metolazone.Approved
TinoridineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Metolazone can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Metolazone.Approved
TizanidineThe risk or severity of adverse effects can be increased when Metolazone is combined with Tizanidine.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Metolazone.Approved
TolazolineMetolazone may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Metolazone.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Metolazone is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Metolazone.Approved
TolterodineThe serum concentration of Metolazone can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramateMetolazone may increase the hypokalemic activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Metolazone.Approved
ToremifeneMetolazone may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Metolazone.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Metolazone.Approved
TranilastThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Metolazone.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Metolazone.Approved
TravoprostTravoprost may increase the hypotensive activities of Metolazone.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Metolazone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Metolazone is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Metolazone.Approved
TrichlormethiazideMetolazone may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrihexyphenidylThe serum concentration of Metolazone can be increased when it is combined with Trihexyphenidyl.Approved
TrimazosinMetolazone may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanThe serum concentration of Metolazone can be increased when it is combined with Trimethaphan.Approved
Trisalicylate-cholineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Trisalicylate-choline.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Metolazone.Withdrawn
TropicamideThe serum concentration of Metolazone can be increased when it is combined with Tropicamide.Approved
TrospiumThe serum concentration of Metolazone can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Metolazone can be increased when it is combined with Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Metolazone.Approved, Investigational
UmeclidiniumThe serum concentration of Metolazone can be increased when it is combined with Umeclidinium.Approved
UnoprostoneMetolazone may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Metolazone.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Metolazone.Approved
VecuroniumThe serum concentration of Metolazone can be increased when it is combined with Vecuronium.Approved
VenlafaxineVenlafaxine may increase the hyponatremic activities of Metolazone.Approved
VerapamilThe risk or severity of adverse effects can be increased when Metolazone is combined with Verapamil.Approved
VilanterolVilanterol may increase the hypokalemic activities of Metolazone.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Metolazone.Approved, Investigational
VinpocetineMetolazone may increase the hypotensive activities of Vinpocetine.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Metolazone.Approved, Investigational
XylometazolineMetolazone may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Metolazone.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Metolazone can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Metolazone.Withdrawn
ZomepiracThe therapeutic efficacy of Metolazone can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
  • Take with food to reduce gastric irritation.
References
Synthesis ReferenceNot Available
General References
  1. Rosenberg J, Gustafsson F, Galatius S, Hildebrandt PR: Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. Cardiovasc Drugs Ther. 2005 Aug;19(4):301-6. [PubMed:16189620 ]
External Links
ATC CodesC03BA08C03EA12
AHFS Codes
  • 40:28.24
PDB EntriesNot Available
FDA labelDownload (834 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9972
Blood Brain Barrier+0.5944
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.7578
P-glycoprotein inhibitor INon-inhibitor0.8113
P-glycoprotein inhibitor IINon-inhibitor0.5921
Renal organic cation transporterNon-inhibitor0.9223
CYP450 2C9 substrateNon-substrate0.6466
CYP450 2D6 substrateNon-substrate0.8279
CYP450 3A4 substrateNon-substrate0.579
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5788
Ames testNon AMES toxic0.8234
CarcinogenicityNon-carcinogens0.7193
BiodegradationNot ready biodegradable0.9961
Rat acute toxicity1.8955 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9922
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Gd searle llc
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Ucb inc
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral2.5 mg/1
TabletOral5 mg/1
TabletOral2.5 mg
TabletOral5 mg
TabletOral10 mg
Prices
Unit descriptionCostUnit
Zaroxolyn 10 mg tablet2.89USD tablet
Zaroxolyn 5 mg tablet2.75USD tablet
Metolazone 10 mg tablet1.8USD tablet
Zaroxolyn 2.5 mg tablet1.74USD tablet
Metolazone 5 mg tablet1.51USD tablet
Metolazone 2.5 mg tablet1.37USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point256 °CPhysProp
water solubility60.3 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.5Not Available
logS-3.78ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0407 mg/mLALOGPS
logP3.21ALOGPS
logP2.94ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)9.54ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.5 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity94.59 m3·mol-1ChemAxon
Polarizability36.38 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinazolines. These are compounds containing a quinazoline moiety, which is made up of two fused six-member aromatic rings, a benzene ring and a pyrimidine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthyridines
Sub ClassQuinazolines
Direct ParentQuinazolines
Alternative Parents
Substituents
  • Quinazoline
  • Aminotoluene
  • Toluene
  • Secondary aliphatic/aromatic amine
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Vinylogous amide
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Tertiary amine
  • Lactam
  • Carboxamide group
  • Azacycle
  • Secondary amine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
Gene Name:
SLC12A3
Uniprot ID:
P55017
Molecular Weight:
113138.04 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23